Emerging methods for disease monitoring in malignant gliomas

Prakash Ambady, Chetan Bettegowda, Matthias Holdhoff

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

MRI remains the backbone of measuring disease burden and treatment response in individuals with malignant gliomas. Traditional radiographic approaches, however, are largely limited to depicting anatomic changes and are not a direct measure of disease burden. For example, contrast enhancement is related to blood-brain barrier integrity rather than actual tumor size. Without accurate measures of disease, common clinical dilemmas include 'pseudo-progression' (e.g., after chemoradiation) or 'pseudo-response' (e.g., with steroid treatment and antiangiogenic agents), which can lead to delays in therapy, premature discontinuation of successful treatments and to unnecessary surgical procedures. This overview focuses on novel, minimally invasive approaches in the area of imaging and blood-based biomarkers that aim to more accurately determine disease status and response to treatment in malignant brain tumors.

Original languageEnglish (US)
Pages (from-to)511-522
Number of pages12
JournalCNS oncology
Volume2
Issue number6
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Fingerprint

Glioma
Unnecessary Procedures
Angiogenesis Inhibitors
Blood-Brain Barrier
Brain Neoplasms
Biomarkers
Steroids
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Emerging methods for disease monitoring in malignant gliomas. / Ambady, Prakash; Bettegowda, Chetan; Holdhoff, Matthias.

In: CNS oncology, Vol. 2, No. 6, 01.11.2013, p. 511-522.

Research output: Contribution to journalArticle

Ambady, Prakash ; Bettegowda, Chetan ; Holdhoff, Matthias. / Emerging methods for disease monitoring in malignant gliomas. In: CNS oncology. 2013 ; Vol. 2, No. 6. pp. 511-522.
@article{b96f9912853d4c1b8732e96ee9f1359c,
title = "Emerging methods for disease monitoring in malignant gliomas",
abstract = "MRI remains the backbone of measuring disease burden and treatment response in individuals with malignant gliomas. Traditional radiographic approaches, however, are largely limited to depicting anatomic changes and are not a direct measure of disease burden. For example, contrast enhancement is related to blood-brain barrier integrity rather than actual tumor size. Without accurate measures of disease, common clinical dilemmas include 'pseudo-progression' (e.g., after chemoradiation) or 'pseudo-response' (e.g., with steroid treatment and antiangiogenic agents), which can lead to delays in therapy, premature discontinuation of successful treatments and to unnecessary surgical procedures. This overview focuses on novel, minimally invasive approaches in the area of imaging and blood-based biomarkers that aim to more accurately determine disease status and response to treatment in malignant brain tumors.",
author = "Prakash Ambady and Chetan Bettegowda and Matthias Holdhoff",
year = "2013",
month = "11",
day = "1",
doi = "10.2217/cns.13.44",
language = "English (US)",
volume = "2",
pages = "511--522",
journal = "CNS oncology",
issn = "2045-0915",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Emerging methods for disease monitoring in malignant gliomas

AU - Ambady, Prakash

AU - Bettegowda, Chetan

AU - Holdhoff, Matthias

PY - 2013/11/1

Y1 - 2013/11/1

N2 - MRI remains the backbone of measuring disease burden and treatment response in individuals with malignant gliomas. Traditional radiographic approaches, however, are largely limited to depicting anatomic changes and are not a direct measure of disease burden. For example, contrast enhancement is related to blood-brain barrier integrity rather than actual tumor size. Without accurate measures of disease, common clinical dilemmas include 'pseudo-progression' (e.g., after chemoradiation) or 'pseudo-response' (e.g., with steroid treatment and antiangiogenic agents), which can lead to delays in therapy, premature discontinuation of successful treatments and to unnecessary surgical procedures. This overview focuses on novel, minimally invasive approaches in the area of imaging and blood-based biomarkers that aim to more accurately determine disease status and response to treatment in malignant brain tumors.

AB - MRI remains the backbone of measuring disease burden and treatment response in individuals with malignant gliomas. Traditional radiographic approaches, however, are largely limited to depicting anatomic changes and are not a direct measure of disease burden. For example, contrast enhancement is related to blood-brain barrier integrity rather than actual tumor size. Without accurate measures of disease, common clinical dilemmas include 'pseudo-progression' (e.g., after chemoradiation) or 'pseudo-response' (e.g., with steroid treatment and antiangiogenic agents), which can lead to delays in therapy, premature discontinuation of successful treatments and to unnecessary surgical procedures. This overview focuses on novel, minimally invasive approaches in the area of imaging and blood-based biomarkers that aim to more accurately determine disease status and response to treatment in malignant brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=84925884596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925884596&partnerID=8YFLogxK

U2 - 10.2217/cns.13.44

DO - 10.2217/cns.13.44

M3 - Article

VL - 2

SP - 511

EP - 522

JO - CNS oncology

JF - CNS oncology

SN - 2045-0915

IS - 6

ER -